Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Exploring a New Approach to Treating Aggressive Breast Cancers
Scientific Advances

Exploring a New Approach to Treating Aggressive Breast Cancers

By Anna WilliamsNov 22, 2016
Share
Facebook Twitter Email
massimo
Massimo Cristofanilli, MD, professor of Medicine in the Division of Hematology/Oncology, was a co-author of the study.

A new strategy for targeting a protein called GRP78 — overexpressed in many breast cancers — could be used to simultaneously provide diagnostic imaging and deliver treatment for inflammatory breast cancer, according to a recent paper published in the Proceedings of the National Academy of Sciences (PNAS).

Massimo Cristofanilli, MD, professor of Medicine in the Division of Hematology/Oncology, was a co-author of the study.

Inflammatory breast cancer (IBC) is a rare and aggressive form of the disease; although it accounts for less than five percent of breast cancer cases in the United States, it makes up more than 10 percent of related deaths. Additionally, IBC is often misdiagnosed due to its atypical disease presentation and does not respond to many targeted drugs.

Given these challenges, the scientists decided to investigate a “theranostic” approach to treating IBC. Theranostics, a blend of “therapeutic” and “diagnostic,” is an emerging field within the precision medicine movement that combines tools of detection and treatment within a single agent.

To do so, the scientists first needed to pinpoint an appropriate target within IBC cells. After extensive screening, they identified a few candidate proteins. They chose to investigate GRP78, since the protein is known to relocate to the surface of cells during stress conditions, making it easily accessible. High levels of GRP78 in patients with cancer have also been linked to lower survival rates.

In the current study, scientists analyzed specimens taken from a group of patients with IBC and confirmed that GRP78 was more strongly expressed, further indicating that the protein was a good candidate for a molecular target.

Next, the team employed particles that were engineered hybrids of phage — viruses that infect and replicate within bacteria — and herpes simplex virus genes, vectors that could deliver both imaging agents and therapeutic genes directly at the tumor sites.

Using mouse models and human tumor samples, the scientists showed that releasing such a platform on GRP78 allowed for in vivo diagnosis through PET imaging, while also delivering treatment with targeted suicide transgene therapy, which triggers cancer cells to self-destruct.

“This discovery confirms the unique biological features of IBC and demonstrates the importance of multidisciplinary and translational research collaborations to advance the understanding of this aggressive form of breast cancer,” Cristofanilli said.

The strategy has potential for future clinical applications, according to the authors, because it can combine non-invasive imaging for disease monitoring with treatment in a single IV administration. If successfully translated into the clinical setting, the approach might also prove useful in treating other aggressive types of cancer, including aggressive variant prostate cancer.

Cristofanilli also serves as the associate director for Translational Research and Precision Medicine at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

The study was funded by National Cancer Institute Cancer Center Support Grants P30 CA016672 and P30 CA118100, as well as Department of Defense IMPACT Grant W81XWH-09-1-0224, AngelWorks and the Gillson-Longenbaugh Foundation.

Cancer Genetics Research
Share. Facebook Twitter Email

Related Posts

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Identifying Protein Interactions that Promote Cancer Growth

Jun 24, 2022

Combination Treatment May Improve Quality of Life in Kidney Cancer

Jun 23, 2022

Comments are closed.

Latest News

Student Spearheads Ukraine Aid Efforts

Jun 27, 2022

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Identifying Protein Interactions that Promote Cancer Growth

Jun 24, 2022

Combination Treatment May Improve Quality of Life in Kidney Cancer

Jun 23, 2022

Calcium Channel Blockers May Improve Chemotherapy Response

Jun 21, 2022
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
pride7
pride6
pride5
pride4
pride3
pride2
pride1
20220607_Feinberg Campus_0070
20220607_Feinberg Campus_0066
20220607_Feinberg Campus_0054
Northwestern University 2022. Photo by Jim Prisching
20220607_Feinberg Campus_0077

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2022 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.